Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) has received a notification from Nasdaq on April 8, 2025, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until October 6, 2025 to meet the requirement.

To regain compliance, PLRZ's closing bid price must exceed $1.00 for at least 10 consecutive business days. If unsuccessful, the company may qualify for an additional 180-day period, provided it meets other Nasdaq Capital Market listing criteria. Failure to comply could result in delisting from Nasdaq.

Positive

• 180-day grace period granted to regain compliance
• Possibility of additional 180-day extension if certain criteria are met
• Continued listing and trading on Nasdaq during compliance period

Negative

• Stock trading below $1.00 for 30 consecutive business days
• Risk of potential delisting from Nasdaq if compliance not achieved
• No guarantee of regaining compliance with minimum bid requirements

Insights

Financial Regulatory Analyst

Polyrizon's Nasdaq non-compliance notification represents a significant regulatory challenge with material implications for shareholders. With the current share price at $0.361, the company needs a 177% increase to reach the $1.00 minimum threshold required by Nasdaq.

This deficiency notice initiates a standardized process where Polyrizon must regain compliance within 180 days (by October 6, 2025) or potentially face delisting. For a development-stage biotech with a modest $14.3M market cap, this creates substantial pressure on management to implement remedial measures.

The most common solutions include:

• A reverse stock split (which artificially increases share price without changing fundamentals)
• Capital raising (potentially dilutive to existing shareholders)
• Achieving significant developmental milestones that naturally elevate share price

If delisting ultimately occurs, consequences would likely include reduced liquidity, access to capital markets, institutional investor exodus, and diminished market visibility - all particularly problematic for an early-stage biotech that typically requires ongoing capital access to fund development programs.

While many companies successfully address similar deficiencies, the substantial price gap and Polyrizon's developmental stage create heightened execution risk in meeting compliance requirements within the allocated timeframe.

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its ordinary shares was below $1.00 per share for the last 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until October 6, 2025, to regain compliance with the minimum bid price requirement. During the compliance period, the Company’s ordinary shares will continue to be listed and traded on the Nasdaq Stock Market. To regain compliance, the closing bid price of the Company’s ordinary shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.

If the Company is not in compliance by October 6, 2025, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market with the exception of the minimum bid price requirement and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s ordinary shares will be subject to delisting.

The Company intends to monitor the closing bid price of its ordinary shares between now and October 6, 2025, and will consider available options to resolve the Company’s noncompliance with the minimum bid price requirement as may be necessary. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What is the deadline for Polyrizon (PLRZ) to regain Nasdaq compliance?

Polyrizon has until October 6, 2025 to regain compliance with Nasdaq's minimum bid price requirement.

What must PLRZ stock price reach to maintain Nasdaq listing?

PLRZ's closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days.

What happens if Polyrizon (PLRZ) fails to meet Nasdaq's minimum bid requirement by October 2025?

If PLRZ fails to comply, it may receive an additional 180-day period, or face delisting from Nasdaq if requirements aren't met.

Why did Polyrizon (PLRZ) receive a Nasdaq deficiency notice in April 2025?

PLRZ received the notice because its closing bid price remained below $1.00 for 30 consecutive business days.